Yiping He

Journal Article Prostate · March 2024 BACKGROUND: Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous stu ... Full text Link to item Cite

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Journal Article Nat Commun · January 25, 2024 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. ... Full text Link to item Cite

Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival.

Journal Article Commun Biol · January 3, 2024 There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable target. In this manuscript, we identify that HSF1 regulates the ... Full text Open Access Link to item Cite

View All Publications

Education, Training & Certifications

University of Pennsylvania · 2002 Ph.D.

Yiping He

Current Appointments & Affiliations

Recent Publications

Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival.

Recent Grants

The role of focal adhesion kinase in therapy resistant prostate tumors

ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas

Glutaminase I isoforms as personalized biomarkers of prostate cancer

Education, Training & Certifications